01/26/2024 at 3:30 pm EST
Recently, interleukin (IL)-23 and the inflammatory IL-23/T-helper (Th)-17 axis have been identified as central drivers of inflammation related to inflammatory bowel disease (IBD). Science in the field of cytokine-targeting therapies, specifically in the field of IL-23 P19 targeting agents, is evolving rapidly, with the first approval in the class occurring in 2022 and several other agents in late-stage development. While all agents within the anti-IL-23 class will have the ability to bind to and neutralize IL-23 via binding to the P19 domain as an essential function, structural differences in the monoclonal antibody Fc fragment result in each agent having an overall unique clinical profile.
This CME Outfitters symposium at the Crohn’s & Colitis Congress (CCC) 2024, entitled Clean-Up on IL-23: Integrating the Science of Inflammatory Targets into Treatment Decision-making in IBD, will feature an expert panel discussion on the science behind cytokine-targeting therapies and will utilize animated 3-D models to discuss therapeutic mechanisms of action (MOAs) of emerging agents, clinical distinctions between therapies, and individualizing treatments for lasting outcomes for patients with IBD.
Supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
Gastroenterologists, gastroenterology fellows, physician associates (PAs), nurse practitioners (NPs), nurses and pharmacists
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process.
Dr. Allegretti reports the following financial relationships:
Consultant: Abbvie Inc.; Adiso Therapeutics; Bristol Myers Squibb Company; Ferring Pharmaceuticals; Finch Therapeutics; GSK; Iterative Scopes; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc..; Pfizer Inc.; Roivant Sciences; and Seres Therapeutics
Research Support: Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; and Pfizer Inc.
Speakers Bureau: Abbvie Inc.; Bristol Myers Squibb Company; and Janssen Pharmaceuticals, Inc.
Dr. Rubin reports the following financial relationships:
Consultant: AbbVie Inc. ; Alimentiv Inc.; AltruBio; Amgen Inc.; Avalo Therapeutics, Inc.; Bristol Myers Squibb Company; BUHLMANN Diagnostics Corporation; ClostraBio; Connect BioPharma; Datos Health; EcoR1 Capital; Evinature;; Ferring Pharmaceuticals; Image Analysis Group (IAG); Iterative Health; Janssen Pharmaceuticals, Inc.; Lilly; Menten AI; Odyssey Therapeutics; Pfizer Inc.; Prometheus Biosciences; Reistone Biopharma; NeuroLogica Corp.; Sangamo Therapeutics; Shanghai Pharmaceuticals; Biotherapeutics, Inc.; Takeda Pharmaceuticals U.S.A., Inc.; Target RWE; Tissium; and Trellus Health Inc.
Grants: Takeda Pharmaceuticals U.S.A., Inc.
Stock Shareholder (ownership interest): Iterative Health (options available, none purchased); Datos Health (nonstatutory stock options); and AltruBio (options available, none purchased)
Disclosures were obtained from the following peer reviewers and CME Outfitters, LLC, staff, with no disclosures to report:
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Call us at 877.CME.PROS (877.263.7767).